Zydus Cadila has received approval from US health regulator to market Felbamate tablets, used to treat seizures in people with epilepsy, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 400 mg and 600 mg, Zydus Cadila said in a statement today.
Felbamate is an oral drug used to treat seizures in people with epilepsy.
The company will manufacture the drug at its plant in Ahmedabad.
The company has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of the company’s listed entity Cadila Healthcare ended 1.23 per cent down at Rs 464.55 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.